AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06119893
Drug: submucosal 8 mg (2 mL) dexamethasone application
RxNorm normalized name: dexamethasone 2 MG/ML
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The mucoperiosteal flap was applied. After operation, submucosal dexamethasone 8 mg (2 mL) was applied to the operation area as a test group.
Trial: NCT06119893
Drug: submucosal 2 mL 0.9% isotonic sodium chloride application
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The mucoperiosteal flap was applied. After operation, 2 mL 0.9% isotonic sodium chloride was applied to the operation area as a control group
Trial: NCT06439550
Drug: Serplulimab
RxNorm normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg, q3w
Trial: NCT06439550
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: First dose 8mg/kg, maintenance 6mg/kg, q3w
Trial: NCT06439550
Drug: Oxaliplatin + Tegafur
RxNorm normalized name: tegafur
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oxaliplatin (130mg/m2, q3w) + Tegafur (40mg/m2, bid d1-d14, q3w).
Trial: NCT05927012
Drug: KER-047
RxNorm normalized name: KER-047
DrugBank: KER-047 (DB19111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet, daily (or every other day) administration
Trial: NCT05183139
Drug: Ixazomib
RxNorm normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ixazomib capsules
Trial: NCT05183139
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide capsules
Trial: NCT05183139
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide capsules
Trial: NCT05183139
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone tablets
Trial: NCT05186012
Drug: APG-1252
RxNorm normalized name: APGA
DrugBank: Aminopterin (DB08878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APG-1252 administered via intravenous infusion for 30 minutes weekly (Day 1, 8, 15, 22).Every 28 days as a cycle.
Trial: NCT05186012
Drug: Chidamide
RxNorm normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Chidamide 30mg orally BIW. Every 28 days as a cycle.
Trial: NCT05809869
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab 1500mg intravenous infusion on week 1, 5, 9, 13, 17, 21 and 25 for a total of 7 cycles
Trial: NCT05809869
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab 300mg intravenous infusion on week 1 only.
Trial: NCT05244057
Drug: Tenofovir Alafenamide Tablets
RxNorm normalized name: Tenofovir Alafenamide Tablets
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 25mg, p.o., qd for 48 weeks
Trial: NCT05244057
Drug: Pegylated Interferon alfa 2a
RxNorm normalized name: Pegylated-interferon alfa 2a
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90ug, s.c., qw for 48 weeks
Trial: NCT04280692
Drug: Sulfadoxine-Pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sub-curative 500mg/25mg single dose regimen
Trial: NCT04280692
Drug: Piperaquine
RxNorm normalized name: Piperaquine
DrugBank: Piperaquine (DB13941)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Sub-curative 480mg single dose regimen
Trial: NCT04280692
Drug: Primaquine
RxNorm normalized name: Primaquine
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single low dose regimen 0.25 mg base/kg
Trial: NCT06476301
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: To compare the efficacy and safety of rivaroxaban as an early anticoagulant therapy for BPV patients with the traditional postoperative anticoagulant warfarin
Trial: NCT06058546
Drug: low dose Jiuweihuaban Pill
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low dose Jiuweihuaban pill 1 bag(3 g placebo per bag and 9 g Jiuweihuaban pill ),p.o.,tid,for 12weeks.
Trial: NCT06058546
Drug: high dose Jiuweihuaban Pill
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose Jiuweihuaban pill 1 bag(12 g Jiuweihuaban pill ),p.o.,tid,for 12weeks.
Trial: NCT05477264
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy: Tislelizumab combined with radiation~* Tislelizumab: 200mg, IV at 3-week intervals combined with radiotherapy.~* Radiotherapy: 400Gy/20 fractions~Maintenance therapy(after termination of combination therapy)~* Tislelizumab: 200mg IV at 3-week intervals for up to 2 years until disease progression or intolerance.
Trial: NCT05176821
Drug: esomeprazole plus amoxicillin
RxNorm normalized name: esomeprazole, amoxicillin and clarithromycin
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amoxicillin 750mg QID + esomeprazole 20mg QID for 14 days
Trial: NCT05176821
Drug: amoxicillin, furazolidone, bismuth potassium citrate , esomeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amoxicillin 1000mg BID + furazolidone 100mg BID + bismuth potassium citrate 600mg BID + esomeprazole 20mg BID for 14 days
Trial: NCT06577961
Drug: Vorolanib
RxNorm normalized name: Vorolanib
DrugBank: Vorolanib (DB15247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: stage Ⅰ：Vorolanib 200mg QD stage Ⅱ：Vorolanib RP2D QD
Trial: NCT06577961
Drug: cadonilimab
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: stageⅠ：cadonilimab 10mg/kg Q3W stageⅡ：cadonilimab 10mg/kg Q3W
Trial: NCT06214195
Drug: Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)
RxNorm normalized name: Trimo San
DrugBank: Sodium lauryl sulfate (DB00815)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ginseng 6g , Ophiopogon japonicus 12g ,Schisandra chinensis 5g , other secondary Chinese medicines can be added according to the doctor's judgment and the patient's condition，decoction in water, one dose and two decoctions, taken twice a day, continuously for 7 days from the start of each chemotherapy cycle (± 3 days), including anthracyclines and taxanes (the frequency and dosage of medication can be adjusted according to adverse reactions in the later stage); The total duration of medication interventionis 7 days per cycle, with a total of 8 cycles. If the chemotherapy is less than 8 cycles, continue taking for 7 consecutive days from the start of each subsequent trastuzumab cycle (the frequency and dosage can be adjusted based on adverse reactions) until a total of 8 cycles are reached.
Trial: NCT05029037
Drug: Dextrose 500 mL
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of a vial of LEV in 100 mL of water for injection, which is diluted in 400mL of 5% Dextrose for a final volume of 500mL of intravenous fluids, to be applied to the chosen patient, in a drip of 0.5 grams of the placebo solution per minute, for a total of 60 minutes.~Twice a day for seven days.
Trial: NCT06525350
Drug: Glumetinib tablets
RxNorm normalized name: selumetinib
DrugBank: Glumetinib (DB15630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An ATP competitive, highly selective MET receptor tyrosine kinase inhibitor
Trial: NCT06525350
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A chemotherapy drug
Trial: NCT05463757
Drug: Vismodegib
RxNorm normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral vismodegib (Erivedge), taken daily or every other day (depending on doctor's description)
Trial: NCT05463757
Drug: Sonidegib
RxNorm normalized name: Sonidegib
DrugBank: Sonidegib (DB09143)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sonidegib (Odomzo), taken daily or every other day (depending on doctor's description)
Trial: NCT05876806
Drug: Dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib is a 150 mg twice daily capsule administered orally on a continuous basis
Trial: NCT05876806
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametinib is a 2 mg once daily tablet administered orally on a continuous basis.
Trial: NCT04667637
Drug: edaravone dexborneol
DrugBank: Borneol (DB11288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injections of edaravone dexborneol (37.5mg, dissolved in 100ml saline) twice a day for 12 ±2 days.
Trial: NCT05505591
Drug: Cangrelor
RxNorm normalized name: Cangrelor
DrugBank: Cangrelor (DB06441)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cangrelor administration during percutaneous coronary intervention for both chronic or acute coronary syndromes
Trial: NCT04447898
Drug: PPV-06 10 μg
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose + Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
Trial: NCT05736757
Drug: Tissue Plasminogen Activator
RxNorm normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of 50 ug tissue plasminogen activator into the suprachoroidal cavity or subretinal space to assist in bleeding liquefaction
Trial: NCT04447898
Drug: PPV-06 50 μg
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
Trial: NCT04565145
Drug: Kava Dietary Supplement
RxNorm normalized name: KAVA
DrugBank: Kava (DB01322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be given three 75mg kava capsules per day for one week
Trial: NCT06323824
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Methadone~Possible formulations:~10 and 40 mg tablets
Trial: NCT06323824
Drug: Buprenorphine (BUP)
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug: Buprenorphine (BUP)~Possible formulations:~A. Buprenorphine 225 mcg to 24 mg 225 mcg to 32 mg per day~B. Buprenorphine (Extended release) 300 mg q 28 days (Sublocade) 100 mg q 28 days (Sublocade) 8 mg q 7 days (Brixadi) 16 mg q 7 days (Brixadi) 24 mg q 7 days (Brixadi) 32 mg q 7 days (Brixadi) 64 mg q 7 28 days (Brixadi) 96 mg q 7 28 days (Brixadi) 128 mg q 7 28 days (Brixadi)
Trial: NCT06578546
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100mg d1, 200mg d2, 400mg d2-21, oral (Adjusted according to the plasma concentration of venetoclax on day 4)，every 28 days for a treatment cycle.
Trial: NCT06578546
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 75mg/m2 qd, d1-d7, subcutaneous injection, every 28 days for a treatment cycle.
Trial: NCT06578546
Drug: Orebatinib
RxNorm normalized name: Rebastinib
DrugBank: Rebastinib (DB13005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg qod, d4-d21, oral, every 28 days for a treatment cycle.
Trial: NCT04735510
Drug: cyclosporine ophthalmic emulsion 0.05%
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive restasis
Trial: NCT04118387
Drug: Acetazolamide + supplemental oxygen + PAP therapy
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Every participant will undergo measurement of the apneic threshold. The apneic threshold (AT) can be determined by inducing central apnea using non-invasive ventilation (NIV) or eliminating central apnea using supplemental CO2. The requisite change to induce central apnea is referred to as the CO2 reserve, which can be positive or negative. The central apnea index and the apneic threshold will be measured while participants receiving medication or oxygen (or both). In addition, participants will get PAP therapy during all the conditions.
Trial: NCT06388135
Drug: Serplulimab Combined With Nab-paclitaxel and Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serplulimab (200 mg), cisplatin (60-75 mg/m2), and nab-paclitaxel (135 mg/m2) administered intravenously at the beginning of every 3-week cycle.
Trial: NCT06388135
Drug: nab-paclitaxel，Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel，Cisplatin
Trial: NCT06507410
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous propofol infusion will be given with syringe pump for maintenance, with the initial rate set at 25-75 mic/kg/min IV during the first 10-15 min. To avoid administering sedatives at rates greater than clinically necessary, infusion rates will be gradually titrated to 25-50 mic/kg/min and regulated with the clinical response, with an onset of peak drug action expected to occur within 2 min.
Trial: NCT06507410
Drug: Propofol combined with clonidine
RxNorm normalized name: Propofol
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 2 μg/kg of clonidine for injection intravenously 30 min before induction of sedation, administered over 10 min.
Trial: NCT05484206
Drug: VIR-2218
RxNorm normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIR-2218 given by subcutaneous injection.
Trial: NCT05484206
Drug: VIR-3434
RxNorm normalized name: Immunoglobulin G1 [238-alanine,332-leucine,334-glutamic acid,430-leucine,436-serine], anti-(hepatitis B virus surface antigen) (human monoclonal VIR-3434 γ1-chain), disulfide with human monoclonal VIR-3434 λ-chain, dimer
DrugBank: Tobevibart (DB18986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIR-3434 given by subcutaneous injection.
Trial: NCT06008652
Drug: DR-0201
RxNorm normalized name: Dr. Numb
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DR-0201 is a bi-specific antibody
Trial: NCT05005507
Drug: JNJ-73763989
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-73763989 will be administered subcutaneously once every 4 weeks.
Trial: NCT05005507
Drug: PegIFN-alpha-2a
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFN-alpha-2a will be administered subcutaneously once weekly.
Trial: NCT05005507
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil film-coated tablet will be administered orally once daily.
Trial: NCT05005507
Drug: ETV
RxNorm normalized name: Metvixia
DrugBank: Methyl aminolevulinate (DB00992)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ETV film-coated tablet will be administered orally once daily.
Trial: NCT05048901
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Cabozantinib 40-60 mg daily .every 4 weeks as a cycle
Trial: NCT05048901
Drug: Lanreotide
RxNorm normalized name: Lanreotide
DrugBank: Lanreotide (DB06791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanreotide 120 mg deep SC on day 1 every 4 weeks.every 4 weeks as a cycle
Trial: NCT05511870
Drug: Etripamil Nasal Spray 70mg
RxNorm normalized name: etripamil
DrugBank: Etripamil (DB12605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etripamil NS 70 mg will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
Trial: NCT00000668
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000440
Drug: naltrexone (Revia)
RxNorm normalized name: naltrexone Oral Tablet [ReVia]
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000440
Drug: sertraline (Zoloft)
RxNorm normalized name: sertraline Oral Solution [Zoloft]
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05708248
Drug: pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg pentoxifylline tablets twice daily with meals for 6 months
Trial: NCT05002231
Drug: Losmapimod 15 mg oral tablet
RxNorm normalized name: Losmapimod
DrugBank: Losmapimod (DB12270)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one losmapimod 15 mg tablet by mouth under fasted conditions.
Trial: NCT05002231
Drug: Losmapimod two 7.5 mg oral tablets
DrugBank: Losmapimod (DB12270)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive two losmapimod 7.5 mg tablets by mouth under fasted conditions.
Trial: NCT05002231
Drug: Losmapimod one 15 mg oral tablet
RxNorm normalized name: Gel-One
DrugBank: Losmapimod (DB12270)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one losmapimod 15 mg tablet by mouth under fed conditions.
Trial: NCT05079672
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine injectable solution, at the rate of 0,3μg/ kg/h, will be infused from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by-pass.
Trial: NCT04691362
Drug: Tranexamic Acid Oral Product
RxNorm normalized name: tranexamic acid Oral Product
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 2 grammes tranexamic acid 2 hours before skin incision and 2 grammes oral tranexamic acid 4 hours after first administration
Trial: NCT04691362
Drug: Tranexamic acid injection
RxNorm normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 1 gramme tranexamic acid 30 minutes before skin incision and 1 gramme intravenous tranexamic acid 4 hours after first administration
Trial: NCT05395117
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive a single dose of midazolam in the morning of Day 1 and in the morning of Day 15 in both the arms.
Trial: NCT05395117
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive digoxin as a single dose administered with rosuvastatin at the same time in the morning of Day 2, Day 6, and in the morning of Day 16 in both the arms.
Trial: NCT05164770
Drug: Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanubrutinib+R-CHOP Regimen: Zanubrutinib 160mg bid; R-CHOP: Rituximab 375mg/m2 d0, Cyclophosphamide 750mg /m2 d1, Doxorubicin 50mg /m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg /m2 or Vindesine 3mg /m2 d1, Prednisone 100mg d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~Zanubrutinib+R-DA-EPOCH Regimen: Zanubrutinib 160mg bid; R-DA-EPOCH: Rituximab 375mg/m2 d0, Etoposide 50mg/ m2, Epirubicin 15mg/ m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide (CTX) 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~Zanubrutinib+R-HD MTX Regimen: Zanubrutinib 160mg bid; R-HD MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/m2 d1. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.
Trial: NCT05006079
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: immediate release oral 15mg dose
Trial: NCT05006079
Drug: Alprazolam
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral 0.25mg dose
Trial: NCT05159531
Drug: PrEP
RxNorm normalized name: X-Prep
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive Descovy® 200/25mg 1 tablet once daily for 72 weeks.
Trial: NCT04928612
Drug: CBP-1018
RxNorm normalized name: CBPC
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CBP-1018 for injection, IV infusion
Trial: NCT06328205
Drug: Lidocaine Hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: When no blood or cerebrospinal fluid is aspirated, the blocking drug can be injected \[20 g/L lidocaine injection\]. once a day. 1 ml per time.
Trial: NCT04528667
Drug: STI-5656
RxNorm normalized name: STI-1499
DrugBank: STI-1499 (DB16487)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STI-5656 (abivertinib maleate) is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor.
Trial: NCT00002234
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002234
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no